The Thiocarboxanilides UC-10 and UC-781 Have an Additive Inhibitory Effect against Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Replication in Cell Culture When Combined with other Antiretroviral Drugs
Free accessResearch articleFirst published online June, 1997
The Thiocarboxanilides UC-10 and UC-781 Have an Additive Inhibitory Effect against Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Replication in Cell Culture When Combined with other Antiretroviral Drugs
The thiocarboxanilides represent a structural class of potent and selective human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors. Combinations of the clinical candidate thiocarboxanilides UC-10 (oxime ether derivative) and UC-781 (pentenyloxy ether derivative) with a variety of nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs), two HIV protease inhibitors and one fusion/uncoating inhibitor were evaluated for their inhibitory effects on HIV-1 RT activity and HIV-1 replication in CEM cell cultures. The inhibitory activity of the NNRTIs including UC-10, UC-781, nevirapine, BHAR α-APA, 8-chloro-TIBO, MKC-442 and the quinoxaline HBY 097 against HIV-1 RT was highly dependent on the nature of the template/primer used in the HIV-1 RT reaction. However, fractionary inhibitory concentration (FIC) indexes for all drug concentrations evaluated in the combination experiments of UC-781 and the other NNRTIs fell within the range 0.5–1.5. This points to a predominantly additive effect of the thiocarboxanilides and other NNRTIs in the inhibition of HIV-1 RT. Similar FIC indexes were observed for the combination of UC-781 with the NRTI triphosphates AZT-TP, d4T-TP, ddCTP, ddATP and 3TC-TP and the NRTI diphosphate PMEApp against HIV-1 RT. All these drug combinations showed similar additive inhibitory effects on HIV-1 replication in cell culture. Also, the combinations of UC-10 or UC-781 with the protease inhibitors Ro31–8959/008 and ABT 84538.0 and the fusion/uncoating inhibitor bicyclam JM 3100 showed an additive effect (FIC within the 0.5–1.5 range). Thus, irrespective of the nature of the drugs, their combination with the thiocarboxanilides proved merely additive. In no case were antagonistic anti-HIV activity or increased cytotoxicity observed. In conclusion, thiocarboxanilides combined with a variety of clinically used anti-HIV agents result in additive anti-HIV activity.
BabaMPauwelsRHerdewijnPDe ClercqEDesmyterJ & VandeputteM (1987a) Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochemical and Biophysical Research Communications142:128–134.
2.
BabaMPauwelsRBalzariniJHerdewijnPDe ClercqE & DesmyterJ (1987b) Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrobial Agents and Chemotherapy31:1613–1617.
3.
BalzariniJ & De ClercqE (1996) Kinetic and inhibitory properties of nucleoside and non-nucleoside reverse transcriptase inhibitors. Methods in Enzymology275:472–502.
4.
BalzariniJHolyAJindrichJNaesensLSnoeckRScholsD & De ClercqE (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activity of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrobial Agents and Chemotherapy37:332–338.
5.
BalzariniJPérez-PérezM-JVelázquezSSan-FélixACamarasaM-JDe ClercqE & KarlssonA (1995) Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proceedings of the National Academy of Sciences, USA92:5470–5474.
6.
BalzariniJBrouwerWGDaoDCOsikaEM & De ClercqE (1996a) Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrobial Agents and Chemotherapy40:1454–1466.
7.
BalzariniJPelemansHAquaroSPernoC-FWitvrouwMShihC-KDe ClercqE & KarlssonA (1996b) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Molecular Pharmacology50:394–401.
8.
BuckheitRWJKinjerskiTLFliakas-BoltzVRussellJDStupTLPallanschLABrouwerWGDaoDCHarrisonWA & SchultzRJ (1995) Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrobial Agents and Chemotherapy39:2718–2727.
9.
De ClercqE (1995a) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry38:2491–2517.
10.
De ClercqE (1995b) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews8:200–239.
11.
De ClercqEYamamotoNPauwelsRBabaMScholsDNakashimaHBalzariniJDebyserZMurrerBASchwartzDThorntonDBridgerGFrickerSHensonGAbramsM & PickerD (1992) Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proceedings of the National Academy of Sciences, USA89:5286–5290.
12.
ElionGBSingerS & HitchingsGH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combination of biochemically related antimetabolites. Journal of Biological Chemistry208:477–488.
13.
KempfDJMarshKCDenissenJMcDonaldEVasavanondaSFlentgeCGreenBGFinoLParkCKongXWideburgNESaldivarARuizLKatiWMShamHLRobinsTStewartKDPlattnerJJLeonardJ & NorbeckD (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease with high oral bioavailability in humans. Proceedings of the National Academy of Sciences, USA92:2484–2488.
14.
KleimJ-PBenderRKirschRMeichsnerCPaessensARosnerMRubsamen–WaigmannHKaiserRWichersMSchneweisKEWinklerI & RiessG (1995) Preclinical evaluation of HBY 097, a new nonnucleoside inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy39:2253–2257.
15.
LarderBAKempSD & HarriganPR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science269:696–699.
16.
McMahonJBBuckheitRWJGulakowskiRJCurrensMJVisticaDTShoemakerRHStinsonSFRussellJDBaderJPNarayananVLSchultzRJBrouwerWGFelauerEE & BoydMR (1996) Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. Journal of Pharmacology and Experimental Therapeutics276:298–305.
17.
MedinaDJHsiungGD & MellorsJW (1992) Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Antimicrobial Agents and Chemotherapy36:1127–1130.
18.
MerluzziVJHargraveKDLabadiaMGrozingerKSkoogMWuJShihC-KEcknerKHattoxSAdamsJRosenthalASFaanesREcknerRJKoupRA & SullivanJL (1990) Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science250:1411–1413.
19.
MitsuyaH & BroderS (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proceedings of the National Academy of Sciences, USA83:1911–1915.
20.
MitsuyaHWeinholdKJFurmanPASt ClairMHLehrmanS NusinoffGalloRCBolognesiDBarrDW & BroderS (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proceedings of the National Academy of Sciences, USA82:7096–7100.
21.
PauwelsRBalzariniJScholsDBabaMDesmyterJRosenbergIHolyA & De ClercqE (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrobial Agents and Chemotherapy32:1025–1030.
22.
PauwelsRAndriesKDebyserZVan DaelePScholsDStoffelsPDe VreeseKWoestenborghsRVandammeA-MJanssenCGMAnnéJCauwenberghGDesmyterJHeykantsJJanssenMACDe ClercqE & JanssenPAJ (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylactamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA90:1711–1715.
23.
RobertsNAMartinJAKinchingtonDBroadhurstACraigJCDuncanIBGalpinSAHandaBKKayJKröhnALambertRWMerrettJHMillsJSParkesKEBRedshawSRitchieAJTaylorDLThomasGJ & MachinPJ (1990) Rational design of peptide-based HIV proteinase inhibitors. Science248:358–361.
24.
RomeroDLBussoMTanC-KReusserFPalmerJRPoppeSMAristoffPADowneyKMSoAGResnickL & TarpleyWG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA88:8806–8810.
25.
SmithMS & PaganoJS (1991) Inhibition of human immunodeficiency virus type 1 replication by guanosine analogues and lack of synergistic antiviral effect of acyclovir with 3′azido-3′-deoxythymidine. Antiviral Research2:29–34.
26.
SoudeynsHYaoX-JQiBelleauB GaoKrausJ-LNguyen-BaNSpiraB & WainbergMA (1991) Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrobial Agents and Chemotherapy35:1386–1390.
27.
TanakaHTakashimaHUbasawaMSekiyaKInouyeNBabaMShigetaSWalkerRTDe ClercqE & MiyasakaT (1995) Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxy-ethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HTV-1 agents. Journal of Medicinal Chemistry38:2860–2865.
28.
VaccaJPDorseyBDSchleifWALevinRBMcDanielSLDarkePLZugayJQuinteroJCBlahyOMRothESardanaWSchlabachAJGrahamPICondraJHGotlibLHollowayMKLinJChenI-WVastagKOstovicDAndersonPSEminiEA & HuffJR (1994) L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences, USA91:4096–4100.
29.
VogtMWHartshornKLFurmanPAChouT-CFyfeJAColemanLACrumpackerCSchooleyRT & HirschMS (1987) Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science235:1376–1379.
30.
YoungSDBritcherSFTrailLOPayneLSLummaWCLyleTAHuffJRAndersonPSOlsenDBCarrollSSPettiboneDJO'BrienJABallRGBalaniSKLinJHChenI-WSchleifWASardanaWLongWJByrnesVW & EminiEA (1995) L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy39:2602–2605.
